Press Release
8 December 2021
Cellular Goods PLC
("Cellular Goods" or "The Company")
Grant of Options to Chief Executive Officer
Cellular Goods (LSE: CBX), a UK-based provider of premium consumer products based on lab-made cannabinoids, announces that Anna Chokina, chief executive, has been granted share options over a total of 20 million ordinary shares in the Company ("Options") at an exercise price per share of 7.64p.
The exercise price of the options is the 30-day VWAP (volume weighted average price) to 12 November 2021, the date on which Ms Chokina accepted the Company's offer, subject to contract. Enterprise Management Incentive options over 3,448,262 ordinary shares will vest on 6 December 2022 and are exercisable for ten years from grant, subject to the rules of the Company's option scheme. Non-tax advantaged options over 16,551,738 ordinary shares will vest as to 3,218,404 shares on 6 December 2022, as to 555,555 shares on 6 January 2023, as to 555,555 shares each month thereafter with any remaining shares vesting on 6 December 2024. These options are also exercisable for ten years from date of grant, subject to the rules of the scheme.
The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
For further information please contact:
| Cellular Goods | |
| Anna Chokina Chief Executive Neil Thapar Investor Relations | via Tancredi +44 207 887 7633
+44 787 645 5323 |
| Tennyson Securities | |
| Corporate Broker Peter Krens |
+44 207 186 9030 |
| Novum Securities | |
| Corporate Broker Colin Rowbury Jon Belliss |
+44 207 399 9427 |
| Tancredi Intelligent Communication | |
| Media Relations Helen Humphrey Edward Daly Charlie Hobbs cellulargoods@tancredigroup.com |
+44 744 922 6720 +44 786 143 0057 +44 789 755 7112 |
About Cellular Goods PLC
Cellular Goods is a UK-based provider of premium consumer products based on lab-made cannabinoids. It was established in August 2018 to develop efficacy-led and research-backed cannabinoid products. The initial focus is on three product verticals: premium CBG skincare and CBD ingestible and topical athletic recovery products, with the first products launched in December 2021 initially through the Company's website.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
